AUTHOR=Chen Yen-Cheng , Chuang Chia-Hsien , Miao Zhi-Feng , Yip Kwan-Ling , Liu Chung-Jung , Li Ling-Hui , Wu Deng-Chyang , Cheng Tian−Lu , Lin Chung-Yen , Wang Jaw-Yuan TITLE=Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer JOURNAL=Frontiers in Oncology VOLUME=12 YEAR=2022 URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.955313 DOI=10.3389/fonc.2022.955313 ISSN=2234-943X ABSTRACT=
Studies have reported the effects of the gut microbiota on colorectal cancer (CRC) chemotherapy, but few studies have investigated the association between gut microbiota and targeted therapy. This study investigated the role of the gut microbiota in the treatment outcomes of patients with metastatic CRC (mCRC). We enrolled 110 patients with mCRC and treated them with standard cancer therapy. Stool samples were collected before administering a combination of chemotherapy and targeted therapy. Patients who had a progressive disease (PD) or partial response (PR) for at least 12 cycles of therapy were included in the study. We further divided these patients into anti-epidermal growth factor receptor (cetuximab) and anti-vascular endothelial growth factor (bevacizumab) subgroups. The gut microbiota of the PR group and bevacizumab-PR subgroup exhibited significantly higher α-diversity. The β-diversity of bacterial species significantly differed between the bevacizumab-PR and bevacizumab-PD groups (